Dr Reddy’s Laboratories Ltd and TR-Pharm announced today a strategic collaboration agreement involving 3 biosimilar products. A total of three products will be registered and subsequently commercialised as part of this agreement by TR-Pharm in Turkey.

TR-Pharm will also manufacture the drug substance and drug product upon completion of its facility investment. Mehmet Goker, General Manager, of the company said: “Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports. This agreement will not only enable more affordable medication but also support our research and development initiatives by building expertise within the country."

MV Ramana, Executive Vice-President & Head, Branded Markets (India and emerging countries), of Dr Reddy's said: “Turkey is a key emerging market and we are pleased to partner with TR-Pharm to ensure that patients in the region get access to our portfolio of high quality biosimilar products. Dr Reddy’s Laboratories is and remains committed to providing access to affordable and innovative drugs to populations around the world, and this partnership will make this happen in Turkey.”

TR-Pharm has begun laying the groundwork for the technology transfer. This collaboration will be an important component of TR-Pharm’s ongoing biological product development and manufacturing business in the region. The partnership will also enable Dr Reddy’s to widen the global footprint of its biosimilar business.

Related Topics